News Notices Hurasia & Newsletter
Notices
Catch up on recent notices and announcements

Developing An Affordable And Accessible COVID-19 Vaccine: Where We Are Now

  • 2020.06.12
  • Admin
d3c087734876060fc8d5ed86527217dc_1591939399_178.png

Developing An Affordable And Accessible COVID-19 Vaccine: Where We Are Now 

Human Asia cordially invites you to join us for us a special online webinar Developing An Affordable And Accessible COVID-19 Vaccine: Where We Are Now’, presented by Dr. Jerome Kim, Director General of the International Vaccine Institute. This event is co-hosted with UAEM Korea and the Korean Association of Human Rights Studies.


This online event will explore current vaccine development efforts towards an effective, affordable and equitable COVID-19 vaccine for all, with particular focus on South Korea's experience so far and future pharmaceutical development.


Overview: 


  • Speaker: Dr Jerome Kim, Director General of the International Vaccine Institute

  • Format: Zoom meeting (online)

    • *The link for the meeting will be emailed to participants after completion of this form. 

  • Time: 1:00 PM - 2:00 PM (KST)

    • *Please sign into the Zoom meeting 10 minutes prior to the beginning of the lecture. There will be instructions on the screen for those who wish to listen in Korean. 

  • Date: Friday 3 July

  • Language: English (with simultaneous interpretation in Korean). 

  • Hosts: Human Asia, UAEM Korea, Korean Association of Human Rights Studies

  • Registration: bit.ly/2XLm5Yo

  • Registration deadline: Thursday 2 July 6:00 PM (KST)


Background:


  • Generally, the rapid global response to developing vaccine candidates against the coronavirus (COVID-19) has been a significant demonstration of governments, the pharmaceutical industry, and scientific experts coming together to confront an ongoing and common crisis.

  • Despite these efforts, however, and the varied promises of politicians, presently it seems unlikely that even an emergency short-term vaccine will be authorised for use within this year. 

  • After its successes in flattening the domestic curve, South Korea and its pharmaceutical firms are now joining global efforts in coronavirus vaccine development, with South Korea's exports of coronavirus test kits having already gathered momentum with high overseas demand. 

  • But once a successful vaccine is produced - whether in South Korea or elsewhere - a number of human rights-related concerns will no doubt emerge. How will countries come together to share knowledge and resources for the vaccine? Will companies allow for a COVID-19 vaccine to be sustainably priced and available to all, or will they tighten intellectual property rights for higher profits? How will governments prioritise who gets the vaccine, if only low doses are available at first?

  • This online event aims to situate South Korea’s experience among international efforts towards developing a COVID-19 vaccine. It explores domestic and international attempts to develop an accessible and affordable vaccine for global implementation, in accordance with the right to health as stipulated within the 1948 Universal Declaration of Human Rights and the 1966 International Covenant on Economic, Social and Cultural Rights. 

  • The webinar aims to highlight the importance of human rights within pharmaceutical development and medical access - with a particular focus on South Korea’s experiences with COVID-19 - through exploring current vaccine development efforts and effective and equitable medical access


Dr. Jerome Kim


Jerome Kim, M.D., is the Director General of the International Vaccine Institute (IVI) and an international expert on the evaluation and development of vaccines. His depth and breadth of scientific experience spans basic research through advanced clinical development. IVI’s oral cholera vaccine, tech-transferred to Shantha Biotechnics (currently part of Sanofi) and EuBiologics and prequalified by the WHO, is used around the world to prevent this deadly diarrheal disease. IVI’s typhoid conjugate vaccine, tech-transferred to SK bioscience and PT Bio Farma, is entering Phase III testing.